Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.502    -0.098 (-16.33%)
Bid:
0.502
Ask:
0.568
Spread: 0.066 (13.147%)
Market Cap: £2.92m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Directorate Changes

20 Feb 2018 07:00

RNS Number : 3598F
Futura Medical PLC
20 February 2018
 

For immediate release

20 February 2018

 

 

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Directorate Changes

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that Derek Martin, the Company's Finance Director, has resigned from the Board and will leave the Company with effect from the date of this announcement to pursue other business interests.

 

Angela Hildreth will join the Company in the role of Finance Director, Chief Operating Officer and Board Director with effect from the date of this announcement. Angela is an experienced executive with a track record gained in financial, operational and strategic roles in healthcare and other industries. Angela's experience includes the AIM market and development-stage companies.

 

Angela was most recently the UK finance director of Shield Therapeutics plc, having joined the business as its financial controller in 2011 when it was an unquoted start-up. Her breadth of roles at the business included finance, business development, human resources and IT.

 

James Barder, Futura's Chief Executive, said: "On behalf of the Board, I would like to thank Derek for his contribution to the development of the Company during almost 10 years as Finance Director having been appointed on 24 September 2008. We wish him all the best in his future activities.

 

"I am delighted to welcome Angela to the role of FD and COO at Futura. Her breadth of knowledge and commercial experience in the pharmaceutical sector will be of great value to the Company at a key stage in our development."

 

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Angela Hildreth (née Bowman), aged 38 years, has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Quaff Box Limited Shield Therapeutics Switzerland AG

Shield TX UK Limited

Phosphate Therapeutics Limited

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

For any further information please contact:

 

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

 

Tel:+44 (0) 20 7496 3000

 

 

For media enquiries please contact:

 

 

Buchanan

 

Mark Court / Sophie Wills / Stephanie Watson

Tel: +44 (0)20 7466 5000

 

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGZZVGFGRZG
Date   Source Headline
20th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20189:05 amRNSSecond Price Monitoring Extn
19th Sep 20189:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness Update
29th Aug 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSTPR 100: UK Regulatory Submission
13th Jun 20186:22 pmRNSResult of AGM
13th Jun 20187:00 amRNSAGM Statement
31st May 20186:20 pmRNSTotal Voting Rights
30th May 201810:20 amRNSBlock Listing Interim Review
25th May 20187:00 amRNSApplication for Block Listing
27th Apr 20185:11 pmRNSNotification of Major Interest in Shares
26th Apr 20187:00 amRNSPhase III efficacy study of MED2002
25th Apr 20187:00 amRNSPositive data from MED2002 PK study
6th Apr 201812:13 pmRNSNotice of AGM
14th Mar 20187:00 amRNSPreliminary Results
13th Mar 20187:00 amRNSPositive Interim Data from MED2002 PK study
20th Feb 20187:00 amRNSDirectorate Changes
15th Feb 20187:00 amRNSNotification of Preliminary Results
31st Jan 201810:39 amRNSTotal Voting Rights
4th Jan 20187:00 amRNSPublication of Positive MED2002 Clinical Data
3rd Jan 20183:08 pmRNSDirector/PDMR Shareholding
2nd Jan 20183:50 pmRNSRemuneration of Non-Executive Directors and TVR
29th Nov 20177:00 amRNSMED2002: Regulatory, Clinical & Commercial Update
29th Nov 20177:00 amRNSMED2002: PK Study Commences
24th Nov 20171:08 pmRNSBlock Listing Update
23rd Oct 20173:30 pmRNSPDMR Dealing
16th Oct 20177:00 amRNSFurther Positive Market Research Data for MED2002
13th Sep 20177:00 amRNSDirectors' / PDMR Dealing and Grant of Options
12th Sep 20177:00 amRNSInterim Results
1st Sep 201712:24 pmRNSNotification of Major Interest in Shares
23rd Aug 201710:32 amRNSCSD500: Termination of Licensing Agreement
22nd Aug 20173:59 pmRNSNotification of Half Year Results
4th Jul 20177:00 amRNSInvestor Presentation on MED2002
14th Jun 20175:00 pmRNSResult of AGM
14th Jun 20177:00 amRNSAGM Statement
31st May 20177:00 amRNSMED2002 Regulatory Update
31st May 20177:00 amRNSTotal Voting Rights
22nd May 20177:00 amRNSBlock Listing Update
20th Apr 20179:45 amRNSNotice of AGM
4th Apr 201712:11 pmRNSNotification of Major Interest in Shares
4th Apr 201712:10 pmRNSNotification of Major Interest in Shares
23rd Mar 20177:00 amRNSPreliminary Results
22nd Mar 20177:00 amRNSLicenses CSD500 in Portugal
6th Mar 20177:00 amRNSResearch Confirms MED2002's US$1 Billion Potential
6th Mar 20177:00 amRNSMED2002 Additional Patent Filing
23rd Jan 20171:00 pmRNSNotice of Preliminary Results
18th Jan 20174:30 pmRNSDirector's dealings
13th Jan 20175:45 pmRNSDirector / PDMR Dealing and Grant of Options
12th Jan 20173:00 pmRNSDirector / PDMR Dealing and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.